231例非小细胞肺癌术后生存和预后分析

被引:12
作者
罗扬
冯奉仪
要洁
张湘茹
王绿化
张德超
机构
[1] 中国医学科学院中国协和医科大学肿瘤医院内科
关键词
非小细胞肺癌; 根治术; 生存期; 预后因素;
D O I
暂无
中图分类号
R734.2 [肺肿瘤];
学科分类号
摘要
目的:总结Ⅱ期和Ⅲa期非小细胞肺癌根治术后的生存情况和评价影响预后的因素。方法:回顾性分析本院1999年1月~2001年3月行根治术的Ⅱ期和Ⅲa期非小细胞肺癌231例患者的临床资料。评价指标为无瘤生存期和生存期。结果:中位随访时间为2.13年,中位无瘤生存期为1.49年,仍未达到中位生存期。分期和淋巴结转移数目为有显著统计学意义的预后因素,而性别、年龄、病理类型、分化程度、根治手术范围、有无脉管瘤栓、是否行术后辅助放化疗对生存率无影响。结论:Ⅱ期和Ⅲa期非小细胞肺癌根治术后的无瘤生存期和生存期仍不理想。
引用
收藏
页码:36 / 38
页数:3
相关论文
共 11 条
[1]  
Postoperativeradiotherapyinnon-small-celllungcancer:systematicreviewandmeta-analysisofindividualpatientdatafromninerandomisedcontrolledtrials. PORTmeta-analysistrialistsgroup. The Lancet . 1998
[2]  
Non-small-celllungcancer-stalemateorprogress. CarneyDN,HansenHH. The New England Journal of Medicine . 2000
[3]  
PrognosticfactorsinpatientswithsurgicallyresectedstagesⅠandⅡnon-smallcelllungcancer. JaziehAR,HussainM,HowingtonJA,etal. The Annals of Thoracic Surgery . 2000
[4]  
Arandomizedtrialofpost鄄operativeadjuvanttherapyinpatientswithcompletelyresectedstageⅡorⅢAnon-small-celllungcancer. KellerSM,AdakS,WagnerH,etal. The New England Journal of Medicine . 2000
[5]  
Survivalinearly-stagenon-smallcelllungcancer. NesbittJC,PutnamJB,WalshGL,etal. The Annals of Thoracic Surgery . 1995
[6]  
Estrogen-receptor-re鄄latedproteinp29inprimarynon-smallcelllungcarcinoma:pathologicandprognosticcorrelations. VargasSO,LeslieKO,VacekPM,etal. Cancer . 1998
[7]  
Prognosticfactorsforthesurvivalofsurgicallytreatedpatientsfornon-smallcelllungcancer. FernandesOJ,AlmgrenSO,ThaningL,etal. Acta Oncologica . 2003
[8]  
Revisions in the international system for staging lung cancer. Mountain CF. Chest . 1997
[9]  
Americansocietyofclinicaloncologytreatmentofunresectablenon-small-celllungcancerguideline:Update2003. PfisterDG,JohnsonDH,AzzoliCG,etal. JClinOncol . 2004
[10]  
Cisplatin-basedadjuvantchemotherapyinpatientswithcompletelyresectednon-smallcelllungcancer. TheInternationalAdjuvantLungCancerTrialCollaborativeGroup. The New England Journal of Medicine . 2004